Back to top

Bayer Refines Nurandociguat Tablet in New Phase 1 Study, Keeping CKD Pipeline on Track

Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer is launching a new Phase 1 study to compare a fresh tablet version of ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bayer Aktiengesellschaft (BAYRY)